SGLT2-Is can not only improve the prognosis of patients with HF, but alsoimprove the cardiovascular prognosis of patients with T2DM and chronic kidneydisease (CKD) [19, 20]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.